Char D H, Kroll S M, Castro J
Department of Ophthalmology, University of California, San Francisco, School of Medicine, USA.
Trans Am Ophthalmol Soc. 1997;95:171-87; discussion 187-91.
To examine the results of helium ion irradiation in 218 uveal melanoma patients treated more than 10 years ago.
Retrospective review of 218 eyes treated with helium ion radiation for uveal melanoma between 1978 and 1984. Several parametric and non-parametric statistical analysis techniques were used.
In 218 eyes treated with helium ion radiation for uveal melanoma, the mean dimension for largest basal diameter was 11.9 mm (range 5 mm to 24 mm). The mean tumor thickness was 6.7 mm (range 1.3 mm to 14.2 mm). Following helium ion radiation 208 (95.4%) of 218 eyes had local tumor control. At 10 years after radiation 46 (22.4%) of 218 eyes were enucleated; the majority (37 of 46) of enucleations were due to anterior ocular segment complications. At 10 years after radiation 102 (46.8%) of the 218 patients were dead; half had non-tumor related deaths and 51 died from metastatic melanoma. Best corrected visual acuity after radiation was > or = 20/40 in 21 of 93 eyes of patients that were alive and retained their eyes 10 or more years after treatment. In patients with tumors that were less than 6 mm in height and more than 3 mm away from the nerve or the fovea, 13 of 18 (72%) retained > or = 20/40. In contrast, only 11% of the patients with either thicker tumors or those close to the nerve or fovea retained that level of acuity. The actuarial enucleation rate at 5 years was 17.2% (2.7% S.E.) and at 10 years this was 22.4% (3.1% S.E). The recurrence tumor control rate at both 5 and 10 years was 5.3% (S.E 1.7%).
Helium ion radiation of uveal melanoma is associated with good local tumor control and reasonable retention of the treated eye 10 years after treatment. In tumors that are less than 6 mm in thickness and greater than 3 mm from the optic nerve and fovea, many retain excellent vision. Approximately one-half of the deaths 10 years after treatment were due to non-tumor-related causes.
研究10多年前接受治疗的218例葡萄膜黑色素瘤患者的氦离子照射结果。
回顾性分析1978年至1984年间接受氦离子放射治疗的218只眼睛。使用了几种参数和非参数统计分析技术。
在218只接受氦离子放射治疗的葡萄膜黑色素瘤眼中,最大基底直径的平均尺寸为11.9毫米(范围为5毫米至24毫米)。肿瘤平均厚度为6.7毫米(范围为1.3毫米至14.2毫米)。氦离子放射治疗后,218只眼中有208只(95.4%)实现了局部肿瘤控制。放射治疗10年后,218只眼中有46只(22.4%)被摘除眼球;大多数摘除眼球的病例(46例中的37例)是由于眼前节并发症。放射治疗10年后,218例患者中有102例(46.8%)死亡;其中一半死于与肿瘤无关的原因,51例死于转移性黑色素瘤。在治疗后存活并保留眼球10年或更长时间的患者中,93只眼中有21只(22.6%)的最佳矫正视力≥20/40。在肿瘤高度小于6毫米且距视神经或黄斑中心凹超过3毫米的患者中,18例中有13例(72%)的视力≥20/40。相比之下,肿瘤较厚或靠近视神经或黄斑中心凹的患者中,只有11%的患者保持了该视力水平。5年时的精算眼球摘除率为17.2%(标准误2.7%),10年时为22.4%(标准误3.1%)。5年和10年时的复发肿瘤控制率均为5.3%(标准误1.7%)。
葡萄膜黑色素瘤的氦离子放射治疗与良好的局部肿瘤控制相关,且治疗10年后患眼保留率合理。对于厚度小于6毫米且距视神经和黄斑中心凹大于3毫米的肿瘤,许多患者保留了极佳的视力。治疗10年后约一半的死亡是由与肿瘤无关的原因导致的。